The Boston Business Journal (Free subscription) | 07/24/2008
Biogen Idec Inc. has appointed Brian S. Posner to its board of directors, the biotechnology company said Thursday.
Business Wire (Free subscription) | 07/24/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies,
ireland.com (Free subscription) | 07/24/2008
Elan reported a narrower second-quarter loss this morning after the company and partner Biogen Idec boosted sales of their Tysabri multiple sclerosis treatment.
New York Times (Free subscription) | 07/23/2008
Biogen Idec reported a higher-than-expected second-quarter profit on Tuesday as sales of its closely watched multiple sclerosis drug Tysabri surged past Wall Street estimates.
Seeking Alpha (Free subscription) | 07/23/2008
Biogen Idec, Inc. (BIIB) Q2 FY08 Earnings Call Complete Story ยป
World of stocks (Free subscription) | 07/23/2008
TheStreet.com Winners & Losers Tech Winners & Losers: Apple Financial Winners & Losers: CME Group Soars 7/22/2008 1:53 PM EDT Health Winners & Losers: Biogen 7/22/2008 5:44 PM EDT Small-Cap Winners & Losers: Bluegreen 7/22/2008 1:28 PM EDT MOST READ: 3 Stocks That Are Going to Zero Hedge funds are well aware of which stocks are going down the drain. You should be, too. 7/22/2008 11:27 AM EDT Crude...
The Street (Free subscription) | 07/22/2008
Biogen Idec climbs on better-than-expected earnings.
Market Watch (Free subscription) | 07/22/2008
Biogen Idec reports higher second-quarter earnings, boosted largely by strong overseas sales of its multiple sclerosis drugs Avonex and Tysabri.
Boston Globe (Free subscription) | 07/22/2008
KEY RESULTS: The company's 11 percent profit boost was driven by sales of the multiple sclerosis drugs Avonex and Tysabri. Revenue rose 28 percent, with Avonex sales up 14 percent and Tysabri sales more than tripling.
Contract Pharma Breaking News (Free subscription) | 07/22/2008
Biogen Idec 2Q Revenues: $993 million (+28%) 2Q Earnings: $207 million (+11%) YTD Revenues: $1.9 billion (+30%) YTD Earnings: $369.7 million (+16%) Comments: Growth in the quarter was driven by Avonex sales up 14% to $527 million, Tysabri sales up 210% to $147 million, and Rituxan revenues from the unconsolidated joint business arrangement up 21% to $279 million. Tysabri revenue comprised $46 million...
The Triangle Business Journal (Free subscription) | 07/22/2008
Biogen Idec said Tuesday that its core product lineup of drugs contributed to a surge in revenue and higher net income in its fiscal second quarter.
The Boston Business Journal (Free subscription) | 07/22/2008
Biogen Idec Inc. said its core product lineup of drugs contributed to a surge in revenue and higher net income in its fiscal second quarter. (BIIB)
Law Blog - WSJ.com (Free subscription) | 07/22/2008
Biogen Idec posted an 11% rise in second-quarter net income Tuesday on strong sales of multiple-sclerosis drugs Avonex and Tysabri and the company also boosted its 2008 outlook.
The Earth Times Online Newspaper (Free subscription) | 07/22/2008
NEW YORK (Reuters) - Biogen Idec Inc , which this month fended off activist investor Carl Icahn's attempt to place three hand-picked candidates on the board, on Tuesday said second-quarter profit rose 11 percent on strong sales of its multiple sclerosis and cancer drugs.
Boston Globe (Free subscription) | 07/22/2008
A surge in multiple-sclerosis drug sales drove an 11 percent boost in Biogen Idec Inc.'s second-quarter profit, prompting the biotechnology company to boost its full-year outlook and aim for record revenue of $4 billion.
The last article published by a user on Biogen Idec :
sunilnair | 12/25/2007
Biogen Idec Inc.: PharmaVitae Profile Introduction This analysis examines the historical and forecast performance for Biogen Idec in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually...
